DC-CIK联合化疗对晚期结直肠癌患者免疫功能及B7-H4蛋白表达的影响

摘要

目的 探讨树突状细胞联合细胞因子诱导的杀伤细胞(DC-CIK)免疫治疗联合常规化疗对晚期结直肠癌患者免疫功能及B7-H4蛋白表达的影响.方法 选取2012年10月至2014年9月收治的晚期结直肠癌患者110例,随机分为两组,每组各55例.其中对照组接受常规化疗,观察组患者接受DC-CIK联合化疗.对比分析两组患者治疗后的免疫功能及B7-H4蛋白表达情况.结果 对照组患者接受治疗后其外周血中CD4+、CD8+和CD4+/CD8+无显著差异(P>0.05);而观察组患者接受治疗后外周血中CD4+和CD4+/CD8+显著升高,与对照组患者相比有显著差异(P<0.05);观察组患者的肿瘤促进分子CD168、CD133、CD151的含量与对照组患者相比明显降低,肿瘤抑制分子CD9和CD63的含量明显高于对照组患者,而干扰素γ(IFN-γ)显著升高,差异有显著性(P<0.05);此外,观察组患者治疗后的可溶性B7-H4蛋白表达明显低于对照组患者(P<0.05).结论 与单纯化疗相比,DC-CIK联合化疗治疗晚期结直肠癌患者有助于提高患者的免疫功能,降低B7-H4蛋白表达,抑制肿瘤生长,在临床治疗晚期结直肠癌的过程中值得推广应用.%Objective To explore the efficacy of dendritic cells/cytokine induced killer cells adoptive immunotherapy (DC-CIK) combined with chemotherapy in treatment of colorectal cancer and its effect on the expression of B7-H4 protein.Methods 110 patients with advanced colorectal cancer treated in our hospital from October 2012 to September 2014 were selected and randomly divided into two groups, each including 55 cases.The patients in the control group received conventional chemotherapy, the patients in the observation group received DC-CIK combined with chemotherapy.The immune function and B7-H4 protein expression between two groups after treatment were compared.Results The peripheral blood CD4+, CD8+ and CD4+/CD8+ ratio had no significant difference after treatment in the control group (P>0.05), while the peripheral blood CD4+ and CD4+/CD8+ ratio increased significantly in the observation group after treatment (P<0.05).The amount of tumor promoting molecules CD168, CD133 and CD151 was significantly decreased in the observation group compared with the control group , and the tumor inhibitory molecules of CD9, CD63 were significantly higher than those of the control group, whereas the level of IFN-γ significantly increased in the observation group, the difference was statistically significant (P<0.05).In addition, the soluble B7-H4 protein expression was significantly lower than that of the control group after treatment (P<0.05).Conclusion Compared with chemotherapy alone, DC-CIK combined with chemotherapy is helpful to improve the immune function of patients with advanced colorectal cancer, and it can reduce B7-H4 protein expression and inhibit tumor growth.Therefore, it is worthy of popularization and application in the treatment of advanced colorectal cancer.